IP Library › Granted Patent US 7,384,978
Granted Patent B2
US 7,384,978 · App. 11/603,124 · Granted Jun 10, 2008

Compounds and methods for delivery of prostacyclin analogs

Assignee: United Therapeutics Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,384,978
App. No.
11/603,124
Granted
Jun 10, 2008
Kind
B2
Abstract

This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula

Claims (19)

1. An oral pharmaceutical composition comprising a compound having structure I

wherein,

R 1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR 1 are substituted or unsubstituted glycolamide esters;

R 2 and R 3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR 2 and OR 3 form esters of amino acids or proteins, with the proviso that all of R 1 , R 2 and R 3 are not H;

or enantiomers or pharmaceutically acceptable salts thereof; and

and an oral excipient.

2. The composition of claim 1 , wherein R 1 is a substituted or unsubstituted benzyl group.

3. The composition of claim 2 , wherein R 1 is CH 2 C 6 H 5 .

4. The composition of claim 1 , wherein OR 1 is a substituted or unsubstituted glycolamide ester, R 1 is —CH 2 CONR 4 R 5 , R 4 and R 5 may be the same or different and are independently selected from the group consisting of H, OH, substituted and unsubstituted alkyl groups, —(CH 2 ) m CH 3 , —CH 2 OH, and —CH 2 (CH 2 ) n OH, with the proviso that m is 0, 1, 2, 3 or 4, and n is 0, 1, 2, 3 or 4.

5. The composition of claim 4 , wherein one or both of R 4 and R 5 are independently selected from the group consisting of H, —OH, —CH 3 , or —CH 2 CH 2 OH.

6. The composition of claim 4 , wherein both of R 4 and R 5 are H, —OH, —CH 3 , or —CH 2 CH 2 OH.

7. The composition of claim 1 , wherein one or both of R 2 and R 3 are H.

8. The composition of claim 1 , wherein R 2 and R 3 are independently selected from phosphate and groups wherein OR 2 and OR 3 are esters of amino acids, dipeptides, esters of tripeptides and esters of tetrapeptides.

9. The composition of claim 8 , wherein only one of R 2 or R 3 is a phosphate group.

10. The composition of claim 8 , wherein R 2 and R 3 are independently selected from groups wherein OR 2 and OR 3 are esters of amino acids.

11. The composition of claim 10 , wherein one or both of R 2 and R 3 are esters of glycine or alanine.

12. The composition of claim 1 , wherein one of R 2 and R 3 are H.

13. The composition of claim 10 , wherein R 2 is H.

14. The composition of claim 1 , wherein R 1 is H.

Continuity (3)
Continuation 1085148100 · May 24, 2004
Provisional Application 6047240700 · May 22, 2003
Related Publication 20070078182A1 · Apr 5, 2007